Boston Scientific Corporation vs MasterCard Inc — how do they compare? Boston Scientific Corporation trades at $51.12 (market cap $71.46B), while MasterCard Inc trades at $561.9 (market cap $493.34B). The key difference: MasterCard Inc is far larger — about 6.9× Boston Scientific Corporation's market cap, and MasterCard Inc pays a 0.62% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | MA | |
|---|---|---|
Market Cap | $71.46B | $493.34B |
Sector | Health | Consumer Cyclical |
52-Week High | $108.14 | $598.96 |
52-Week Low | $42.63 | $471.55 |
Enterprise Value | $83.55B | $506.38B |
Volume | — | 4,635,698 |
Dividend Yield | — | 0.62% |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $49.31, up slightly by 0.02% on the day, with a bullish technical signal from moving averages despite overbought RSI readings near 77–83. The company reported strong Q2 2026 results, beating EPS estimates with $0.86 actual versus $0.835 expected, and revenue growth of 7.5%. Fundamentals show robust profitability with a net income margin of 17.5% and ROE of 15.52%, though 2026 guidance was trimmed due to WATCHMAN and electrophysiology segment pressures.
BSX presents a compelling investment case with 86% analyst buy ratings and a $67.21 consensus price target implying 36% upside. Key risks include competitive pressures in medical devices and execution on cost savings. The stock's valuation at a P/E of 19.96 appears reasonable given earnings growth, but investors must weigh near-term headwinds against long-term innovation catalysts.
Mastercard (MA) trades at $563.17, up 0.04% on the day, with a bullish technical signal supported by moving averages and strong institutional buying interest. The company continues to deliver robust financial performance, with Q2 2026 EPS of $5.04 beating estimates of $4.77, marking the third consecutive quarterly beat. Revenue growth remains strong, rising from $22.2B in 2022 to $32.8B in 2025, while maintaining net income margins above 45%. Recent news highlights Mastercard's expansion into AI-driven payments and initiatives to connect underbanked populations.
The outlook for MA remains positive given its consistent earnings beats, high profitability, and dominant market position. However, investors should monitor competitive threats from emerging payment technologies like stablecoins and regulatory scrutiny. With 79% analyst buy ratings and a consensus price target of $660.85, Wall Street sees approximately 17% upside potential from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →